Log inSign up
AAOIFI No. 21 screening

Is ACAD halal?

ACADIA Pharmaceuticals Inc.

Halal

ACADIA Pharmaceuticals Inc. passed every check under AAOIFI Shariah standard No. 21: no prohibited business activity, and all three financial ratios are within limits.

Checked: 14 October 2026

Exchange

NASDAQ

Price

19.12

Day

-2.99%

Market cap

$3.24B

Industry

Biotechnology

Sector

Healthcare

What the company does

ACADIA Pharmaceuticals sells Nuplazid (Parkinson's psychosis) and Daybue (Rett syndrome) — the two drugs make up its revenue. Its money comes from prescription-drug sales.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ 36-month average market cap $3.56B = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $956.47M ÷ 36-month average market cap $3.56B = 26.8%

    26.8%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    Interest income $31.72M ÷ annual revenue $1.07B (2025) = 3.0%

    3.0%

    Pass

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $3.24B.

For information (AAOIFI 3/1 note): cash + receivables are 64.4% of total assets (2026-06-30). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500
Among halal stocks
0.00% · #670 of 1454

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyACAD's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →